TG Therapeutics (NASDAQ:TGTX) Shares Gap Up to $13.66

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $13.66, but opened at $17.15. TG Therapeutics shares last traded at $16.31, with a volume of 5,961,876 shares traded.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TGTX. JPMorgan Chase & Co. restated an "overweight" rating and set a $25.00 target price on shares of TG Therapeutics in a research report on Thursday, April 18th. HC Wainwright restated a "buy" rating and set a $45.00 target price on shares of TG Therapeutics in a research report on Thursday, April 18th. B. Riley boosted their target price on TG Therapeutics from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Monday, February 5th. LADENBURG THALM/SH SH restated a "buy" rating and set a $39.00 target price on shares of TG Therapeutics in a research report on Thursday, April 18th. Finally, The Goldman Sachs Group boosted their target price on TG Therapeutics from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Thursday, February 29th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $29.00.

TG Therapeutics Stock Up 16.3 %

The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18. The stock has a market cap of $2.45 billion, a PE ratio of 769.38 and a beta of 2.30. The business has a fifty day moving average of $15.07 and a 200-day moving average of $14.32.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.03. The firm had revenue of $43.97 million during the quarter, compared to analyst estimates of $40.06 million. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. During the same quarter in the previous year, the business earned ($0.39) earnings per share. Equities research analysts anticipate that TG Therapeutics, Inc. will post -0.11 earnings per share for the current year.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the company's stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total transaction of $351,340.00. Following the completion of the sale, the director now owns 215,229 shares in the company, valued at $3,437,207.13. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 9.20% of the stock is owned by company insiders.

Institutional Trading of TG Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. New York State Common Retirement Fund lifted its holdings in TG Therapeutics by 1.2% during the fourth quarter. New York State Common Retirement Fund now owns 56,208 shares of the biopharmaceutical company's stock worth $960,000 after buying an additional 663 shares during the period. Kestra Advisory Services LLC lifted its holdings in TG Therapeutics by 8.2% during the third quarter. Kestra Advisory Services LLC now owns 16,342 shares of the biopharmaceutical company's stock worth $137,000 after buying an additional 1,240 shares during the period. Principal Financial Group Inc. increased its position in shares of TG Therapeutics by 3.9% during the first quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company's stock worth $538,000 after purchasing an additional 1,322 shares in the last quarter. Arizona State Retirement System increased its position in shares of TG Therapeutics by 3.5% during the third quarter. Arizona State Retirement System now owns 40,411 shares of the biopharmaceutical company's stock worth $338,000 after purchasing an additional 1,356 shares in the last quarter. Finally, Valeo Financial Advisors LLC increased its position in shares of TG Therapeutics by 2.4% during the fourth quarter. Valeo Financial Advisors LLC now owns 63,300 shares of the biopharmaceutical company's stock worth $1,081,000 after purchasing an additional 1,500 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.